What can we help you find?
The trial’s main goal is to compare the health status of participants in the combination treatment group with participants in the remdesivir-only group on day 7.
Although researchers still hope to learn what protection immunoglobulin G antibodies offer against re-infection, this study could have broad implications in the development of a COVID-19 vaccine.
Intravenous Immunoglobulin Reduces Hospital Stays, Progression to Mechanical Ventilation in COVID-19 Patients
Intravenous Immunoglobulin helps to improve hypoxia, which can reduce the need for mechanical ventilation.
When treating these diseases, immunoglobulin is effective because of its ability to be used by the immune system to neutralize pathogens, such as pathogenic bacteria, fungi, and viruses.
Myasthenia gravis is most commonly caused by binding of immunoglobulin G (IgG) antibodies to the postsynaptic acetylcholine receptor (AChR), although other receptors may also be involved.
A study found that intravenous immune globulin dosing optimization through alternative dosing weights represents a significant source of waste reduction and cost reduction.
In this study, researchers wanted to evaluate the frequency of reduced immunoglobulin concentrations and its association with immunotherapy and disease course in 2 independent cohorts with multiple sclerosis.
Carefully implemented order sets may encourage evidence-based or institution-specific care though the influence of provider behavior.
Five-day adjuvant IVIG therapy found to significantly reduce viral load in an immunocompromised patient with severe varicella.
The case study included a 45-year-old man diagnosed with stage 3 multiple myeloma who was treated with bortezomib and dexamethasone.
Study Finds Clinical Significance of RBC Immunoglobulin G in PolyTransfused Patients with Thalassemia
The study authors wanted to determine the prevalence and clinical significances of red blood cell-bound immunoglobulin G as detected by flow cytometry in polytransfused patients with thalassemia.
IVIG found to have a good safety profile in pediatric patients, with low risk of severe adverse drug reactions.